Siemens joins with Pfizer for companion diagnostic projects; Dx outfit Lineagen pulls in $3.5M Series C;

> Myriad ($MYGN) must deal with investors spooked about continued reports that CMS reimbursement for its signature BRACAnalysis test will decline. Story

> Salt Lake City-based Lineagen has raised a $3.5 million Series C, even as the molecular diagnostics outfit said it is on track to become profitable by the first half of 2014. Item

> Rheonix, an Ithaca, NY-based molecular diagnostics company, has raised $14 million through a debt and equity private placement. Story (reg. req.)

> Siemens ($SI) will concoct diagnostic tests for some Pfizer ($PFE) drugs, the German conglomerate has disclosed. Story

> The health minister in the Netherlands has approved trials for a DNA blood test to check whether a fetus has Down syndrome. Story

> Vermillion ($VRML), a women's health-focused molecular diagnostics company based in Texas, has brought on a new chief commercial officer. Item

> Veracyte ($VCYT), the newly public molecular diagnostics company and 2013 FierceMedicalDevices Fierce 15 winner, obtained Cigna coverage for its Afirma Gene Expression Classifier, a test meant to help patients avoid unnecessary surgery as part of a thyroid cancer diagnosis. Item

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.